Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination

Details for Australian Patent Application No. 2006313672 (hide)

International Classifications

Event Publications

3 July 2008 PCT application entered the National Phase

PCT publication WO2007/054600 Priority application(s): WO2007/054600

8 December 2011 Application Accepted

Published as AU-B-2006313672

12 January 2012 Application for Amendment

The nature of the amendment is: Amend the invention title to read Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical composition comprising such combination, procedures to obtain the cell line, procedures to produce such combination of glyciosoforms, and sepsis treatment and prevention methods. Address for service in Australia - Watermark Patent and Trade Marks Attorneys Level 2 302 Burwood Road Hawthorn VIC 312

3 May 2012 Amendment Made

The nature of the amendment is: Amend the invention title to read Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical composition comprising such combination, procedures to obtain the cell line, procedures to produce such combination of glycoisoforms, and sepsis treatment and prevention methods 2007

10 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.